Terms: = Prostate cancer AND CCDC6, D10S170, 8030, ENSG00000108091, Q16204, TPC, H4, TST1 AND Prognosis
6 results:
1. A first-in-class HBO1 inhibitor WM-3835 inhibits castration-resistant prostate cancer cell growth in vitro and in vivo.
Mi YY; Ji Y; Zhang L; Sun CY; Wei BB; Yang DJ; Wan HY; Qi XW; Wu S; Zhu LJ
Cell Death Dis; 2023 Jan; 14(1):67. PubMed ID: 36709328
[TBL] [Abstract] [Full Text] [Related]
2. Epigenetic modification-dependent androgen receptor occupancy facilitates the ectopic TSPY1 expression in prostate cancer cells.
Leng X; Liu M; Tao D; Yang B; Zhang Y; He T; Xie S; Wang Z; Liu Y; Yang Y
Cancer Sci; 2021 Feb; 112(2):691-702. PubMed ID: 33185915
[TBL] [Abstract] [Full Text] [Related]
3. Inflammatory markers as prognostic factors in metastatic castration-resistant prostate cancer.
Donate-Moreno MJ; Lorenzo-Sánchez MV; Díaz de Mera-Sánchez Migallón I; Herraiz-Raya L; Esper-Rueda JA; Legido-Gómez O; Rico-Marco S; Salinas-Sánchez AS
Actas Urol Esp (Engl Ed); 2020 Dec; 44(10):692-700. PubMed ID: 33010988
[TBL] [Abstract] [Full Text] [Related]
4. B7-H4 is a potential prognostic biomarker of prostate cancer.
Li H; Piao L; Liu S; Cui Y; Xuan Y
Exp Mol Pathol; 2020 Jun; 114():104406. PubMed ID: 32088189
[TBL] [Abstract] [Full Text] [Related]
5. [Expression of B7-H4 in prostate cancer and its clinical significance].
Qian Y; Yao HP; Shen L; Cheng LF; Zhang LH
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2010 Jul; 39(4):345-9. PubMed ID: 20731031
[TBL] [Abstract] [Full Text] [Related]
6. Global levels of histone modifications predict prostate cancer recurrence.
Ellinger J; Kahl P; von der Gathen J; Rogenhofer S; Heukamp LC; Gütgemann I; Walter B; Hofstädter F; Büttner R; Müller SC; Bastian PJ; von Ruecker A
Prostate; 2010 Jan; 70(1):61-9. PubMed ID: 19739128
[TBL] [Abstract] [Full Text] [Related]